



NOVOGENIA
ANALYZE. LEARN. SOLVE.



Issuer Report as of June 30, 2026

Novogenia AG

formerly Darwin AG

At a Glance

Novogenia Group

in EUR thousands in EUR thousands

Balance Sheet Key Figures*

	30.06.2026	30.06.2025
Total Assets	113,936	155,675
Equity	91,770	101,588
Equity Ratio (%)	80,5	65,3
Trade Receivables	5,116	6,413
Trade Payables	4,957	3,156
Cash and Cash Equivalents	11,972	10,575
Bank Liabilities	5,712	3,110

Income Statement Key Figures*

	01.01. - 30.06.2026	01.01. - 30.06.2025
Group Revenue	25,662	27,619
Gross Profit	9,400	10,931
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-3,540	-3,535
Operating Result (EBIT)	-4,677	-4,875
Financial Result	2,673	6,989
Group Earnings before Taxes (EBT)	-2,004	2,113
Group Earnings after Taxes (EAT)	-2,131	2,038
Group Earnings per Share in EUR**	-0.18	0.17

*unaudited, not reviewed

**calculated based on the current issued share capital of 12,000,000 shares

Letter from the Management Board

Dear Shareholders,

The Novogenia Group experienced a mixed first half of 2026. Revenue in our core business of DNA analyses and the development of personalized dietary supplements and cosmetics based on them increased compared with the prior-year period. This underscores the growing demand for personalized health solutions. At Group level, however, this progress was outweighed by declining revenue in the pharmaceutical and medical device trading and by challenges experienced in individual sales channels. Unlike in the previous year, the Group recorded a loss. A closer look at the individual business areas is necessary to put this development into context.

Business Area Performance

In the business area of DNA analyses and the development of personalized products based on them, the positive revenue trend continued compared with the prior-year period. At the same time, we made a noticeable improvement to the cost base. By contrast, a change to Meta's advertising algorithm had an adverse impact. The resulting reduction in targeting precision led to lower conversion rates and consequently lower revenue for products marketed through this channel. Together with our partners, we are adjusting the management of our marketing activities accordingly to address this challenge.¹

Medical genetics activities within the business area developed positively. The subsidiary HLN Genetik GmbH attracted additional referring physicians and medical institutions, thereby increasing revenue.

In the business area pharmaceutical and medical device trading, regulatory changes led to a noticeable decline in revenue in the first half of 2026 compared with the prior-year period. We have initiated operational countermeasures and expect revenue in this business area to recover in the second half of the year.

The earnings position continues to be shaped by significant expenditure on expanding the core business. Following substantial investment in IT infrastructure in recent years, the focus is now on making consistent use of the platform that has

¹ <https://themediabuyer.northbeam.io/p/h1-2026-meta-cvrs-are-tanking-as-cacs-skyrocket>

been created. Our aim is to realise further efficiency potential and gradually reduce IT costs while continuously enhancing the technological foundation for further growth and the development of NovoDaily.

Operational and Strategic Progress

To further intensify our collaboration with 10X Health Systems, we advanced the joint product pipeline and brought the first new products to market readiness. For example, the expanded MGT Plus methylation test was launched in the United States in August 2026, with further products scheduled to follow in the fourth quarter. The collaboration with 10X Health gives Novogenia access to the world's largest market for direct-to-consumer tests and supports the international scaling of our core business.

Together with our cooperation partner G42 in Abu Dhabi, we advanced extensive preparations for the market launch of the genetic analyses and the personalised nutritional supplements based on them, despite the product launch being delayed by the geopolitical situation in the Middle East. In addition to an initial study to demonstrate improvements in blood values, the results of which are still pending, the main focus was on adapting the products to the Arabic language and cultural environment and preparing production for Halal certification. Despite the geopolitical situation, we continue to regard the partnership as strategically important for accessing the healthcare market in the United Arab Emirates.

The Multi-Cancer Check was launched in March 2026. This blood test enables preliminary screening for 13 types of cancer and expands our range of medical prevention services. In addition, the launch of the new software platform for NovoDaily was successfully completed, providing the IT foundation for significantly faster product launches and processing times.

Construction of the new company site in Hallwang near Salzburg commenced as planned in the first half of the year, and the official groundbreaking ceremony took place in July. The facility, which will cover more than 9,300 square meters, will include modern lab infrastructure, automated production capacity and space for research, development and collaboration. To date, all work is proceeding according to plan, and the Management Board expects completion in early 2028.

The change of name from Darwin AG to Novogenia AG, approved by the 2026 Annual General Meeting, was completed in July. In doing so, we transferred the name of the established core operating brand to the listed parent company. In future, we will operate under a single brand, simplifying how the company is

perceived, increasing Novogenia's visibility and strengthening its strategic positioning in the market and in the capital markets.

Business performance in the first half of 2026 did not meet our expectations in all areas. At the same time, we made progress in our core business, cost base and strategic partnerships. In the second half of the year, our focus will be on the operational execution of new product launches, the stabilization of sales channels impacted by changes to digital platform algorithms and maintaining strict cost control. On this basis, we believe Novogenia remains well positioned in the growing market for personalized prevention and healthcare.

Munich, September 28, 2026

Yours sincerely

Novogenia AG



Dr. Daniel Wallerstorfer

Founder and CEO



Felix Bausch

CIO

Consolidated Income Statement

	01.01. - 30.06.2026	01.01. - 30.06.2025
	EUR	EUR
1. Revenue	25,662,490.53	27,618,861.65
2. Increase or decrease in inventories of finished goods and work in progress	860,514.02	190,440.35
Total output	26,523,004.55	27,809,302.00
3. Other operating income	209,551.64	3,569,558.72
4. Cost of materials:		
a) Cost of raw materials, consumables and supplies and purchased merchandise	-16,607,761.72	-19,711,011.70
b) Cost of purchased services	-724,544.97	-736,916.56
5. Personnel expenses:		
a) Wages and salaries	-5,922,132.14	-6,430,476.28
b) Social security, pension and other employee benefit expenses	-1,335,442.12	-1,444,882.44
6. Depreciation and amortisation		
a) of intangible non-current assets and property, plant and equipment	-1,137,302.47	-1,339,816.38
7. Other operating expenses	-5,682,726.12	-6,591,030.63
Operating result	-4,677,353.35	-4,875,273.43
8. Income from other securities	454,139.52	3,982,816.38
9. Other interest and similar income	483,962.88	626,729.84
10. Income from disposals of and reversals of impairment on financial assets and securities held	2,220,959.75	2,813,572.02
11. Write-downs of financial assets and securities held as current assets	-252,529.73	-150,935.59
12. Interest and similar expenses	-233,597.38	-283,681.82
13. Financial result	2,672,935.04	6,988,500.83
14. Earnings before taxes	-2,004,418.31	2,113,227.40
15. Income taxes	-126,305.94	- 74,736.43
16. Earnings after taxes	-2,130,724.25	2,038,490.97
17. Other taxes	-2,235.32	-998.32
18. Non-controlling interests	232,443.70	42,316.51
19. Consolidated net income	-1,900,515.87	2,079,809.16

Notes to the Consolidated Income Statement

The 7% decline in revenue to EUR 25.7 million and, to a lesser extent, the decrease in total output to EUR 26.5 million was primarily attributable to lower volumes in parallel imports of pharmaceuticals due to regulatory changes. By contrast, the business area of genetic analyses and personalized products based on them recorded positive revenue growth compared with the prior year period.

Other operating income of EUR 0.3 million was below the prior-year level, which included notional reversals of provisions amounting to EUR 2.5 million. These were no longer included in the current financial year. Other operating income for the current year contains no special effects.

Cost savings achieved in materials, personnel and other operating expenses in the first half of 2026 resulted in an improvement in operating performance of around EUR 2.7 million. However, due to the decline in other operating income, this progress was only partially reflected in the reported operating result, which improved by 4.1% year on year to EUR -4.7 million.

The Novogenia Group invests a significant portion of its available financial reserves in broadly diversified securities portfolios. These also performed very well in the first half of 2026 and had a correspondingly positive impact on the financial result (EUR 2.7 million), although not to the same extent as in the previous year.

Consolidated Balance Sheet

ASSETS	30.06.2026	30.06.2025	EQUITY AND LIABILITIES	30.06.2026	30.06.2025
A. Non-current assets	46,552,417.81	44,031,574.75	A. Equity	91,770,397.51	101,587,681.99
I. Intangible assets	7,050,177.50	10,138,313.17	I. Subscribed capital	12,000,000.00	3,000,000.00
1. Concessions, industrial property rights and similar rights and assets acquired for consideration, and licences in such rights and assets	2,081,208.51	3,159,707.00	II. Capital reserve	8,700,001.00	17,700,001.00
2. Goodwill	4,968,968.99	6,618,606.17	III. Retained earnings	28,025,588.37	28,025,588.37
II. Property, plant and equipment	15,202,232.29	5,940,756.56	IV. Difference from currency translation	-8,326.63	-3,095.72
1. Buildings	767,514.73	804,257.73	V. Consolidated retained earnings	43,358,633.51	52,393,596.14
2. Technical equipment and machinery	3,359,709.15	1,921,977.16	VI. Non-controlling interests	-305,498.74	471,592.20
3. Other equipment, operating and office equipment	2,078,095.39	1,614,587.03	B. Provisions	3,533,506.39	15,024,430.49
4. Payments on account and assets under construction	8,996,913.02	1,599,934.64	I. Tax provisions	1,479,256.35	7,846,292.95
III. Financial assets	24,300,008.02	27,952,505.02	II. Other provisions	2,054,250.04	7,178,137.54
1. Equity investments	1,300,008.02	1,302,505.02	C. Liabilities	17,589,271.34	38,592,755.22
2. Securities held as non-current assets	23,000,000.00	26,650,000.45	1. Liabilities to banks	5,712,048.38	3,110,397.68
B. Current assets	64,699,709.79	111,053,806.72	2. Payments received on account of orders	0.00	8,060.00
I. Inventories	11,505,985.55	13,001,290.37	3. Trade payables	4,957,206.24	3,156,050.76
1. Raw materials, consumables and supplies	8,091,023.43	9,289,147.95	4. Other liabilities	1,341,831.78	5,992,717.53
2. Finished goods and merchandise	2,921,520.00	2,210,506.85	5. Liabilities to entities in which an equity interest is held	5,578,184.94	26,325,529.25
3. Payments on account for inventories	9,388.01	415,601.51	D. Deferred income	1,039,206.47	470,549.84
4. Work in progress	484,054.11	1,086,034.06	E. Deferred tax liabilities	3,890.11	
II. Receivables and other assets	13,425,265.16	26,135,689.60			
1. Trade receivables	5,116,278.40	6,413,119.73			
2. Other assets	5,188,887.23	2,617,817.12			
3. Receivables from entities in which an equity interest is held	3,120,099.53	17,104,752.75			
III. Securities held as current assets	27,796,522.52	61,341,348.45			
IV. Cash on hand and bank balances	11,971,936.56	10,575,478.30			
C. Prepaid expenses	2,684,004.69	590,036.07			
D. Deferred tax assets	139.53				
Total assets	113,936,271.82	155,675,417.54	Total equity and liabilities	113,936,271.82	155,675,417.54

Notes to the Consolidated Balance Sheet

The building recognized in the consolidated balance sheet is MEDICOPHARM AG's operating facility. All other premises used by the Group are leased. The significant increase in payments on account and assets under construction was primarily attributable to the start of construction of the new company building in Hallwang near Salzburg in the first half of 2026.

Receivables from entities in which an equity interest is held relate to loans to significant shareholders of Novogenia AG, which are secured by outstanding dividend receivables of these shareholders. The dividend receivables are reported under liabilities to entities in which an equity interest is held. These corresponding items decreased significantly compared with the previous year.

As of June 30, 2026, the Novogenia Group held securities and cash and cash equivalents totaling EUR 39.8 million. Total assets amounted to EUR 113.9 million.

As of 30 June 2025, the share capital comprised 3,000,000 no-par-value shares. At an Extraordinary General Meeting of Novogenia AG, then still operating under the name Darwin AG, held on August 13, 2025, a share split at a ratio of 1:3 was approved. The new shares were created by converting EUR 9,000,000 from the capital reserve into share capital and were issued on September 22, 2025. Share capital therefore amounts to EUR 12,000,000. Equity amounted to EUR 91.8 million, corresponding to an equity ratio of 80.5%.

The increase in liabilities to banks resulted from partial financing of the acquisition of MEDICOPHARM AG, which was drawn down in the second half of 2025.



Novogenia AG

Brienner Straße 7

80333 München

investor.relations@novogenia.com

www.novogenia.com